MORE►
machine learning
Researchers at UT Dallas used an enzyme called TdT to create unique genetic "fingerprints" inside living cells—a breakthrough in biosecurity that could help biotech companies verify cell identity and prevent counterfeiting. The technique, published in Advanced Science, increases randomness in DNA repair to generate one-of-a-kind markers. This cropped image shows a key step—Pol X’s role in the process. [Source: Figure 1, TdT (1D) PUF/Advanced Science]
UT Dallas Researchers ‘Barcode’ Engineered Cells with Patent-Pending Tech to Protect Biotech IP
by Maddie Preston | Sep 27, 2025
The UTD team’s approach adapts a chip-security technique to biology. The breakthrough gives biotech companies a new way to prevent costly misidentification and protect intellectual property.
by Quincy Preston |
Sep 3, 2025
The new federal Alzheimer's hub joins an elite network of 37 centers nationwide. Scientists from UT Southwestern, UT Arlington, and UT Dallas will decode dementia by exploring hypertension's role, analyzing voice patterns with AI, and creating virtual patient models.
MORE►
Dallas Biotech Launches Open-Access AI Tool Targeting One of Brain Drug Discovery’s Toughest Hurdles
by Quincy Preston |
Aug 20, 2025
With just 2% to 6% of small-molecule drugs able to cross the blood-brain barrier, researchers and drugmakers face steep odds. Lantern Pharma’s tool, the company’s CEO says, could be “a paradigm shift” in developing treatments for conditions ranging from brain cancers to Parkinson’s disease.
MORE►
by Maddie Preston |
Aug 8, 2025
The funding supports UT Arlington researcher Junzhou Huang, whose team recently ranked first in protein contact prediction and placed sixth overall in an international AI challenge competing against Google DeepMind, the University of Washington, and others.
MORE►
Tango founder Pranav Tyagi (left) and the company's new CEO, Jon Elliott [Photo: Jon Elliott/LinkedIn]
Tango Appoints Former Bluebeam Leader as Its New CEO
by Lance Murray | May 7, 2025
The Dallas-based provider of cloud-based real estate and facilities management software solutions has appointed veteran executive Jon Elliott to succeed Pranav Tyagi, who founded Tango and served as its leader for 17 years.
MORE►
by Lance Murray |
Aug 22, 2024
"The new capital will help us continue our momentum in deploying integrated solutions and best-in-class service for fund managers in the private credit and broadly syndicated bank debt sector," Siepe CEO and founder Michael Pusateri said. In conjunction with the new funding, Siepe has appointed Mark Schultis as president.
MORE►
by Lance Murray |
Dec 6, 2023
UT Arlington principal investigator Dr. Suvra Pal said that previous studies modeling the probability of a cancer cure—also called the cure rate—"used a generalized linear model." The new statistical modeling method published by Pal and his student is said to be 30% more effective in predicting who will be cured of cancer and who will need further treatment.
MORE►
by Lance Murray |
Nov 9, 2023
Save the Elephants will deploy a small fleet of drones equipped with high resolution and infrared cameras to capture elephant behavioral data, which will then be processed by Colossal’s machine learning core to develop algorithms that will label elephants and automatically identify individual and collective social behavior.
MORE►
Tango founder and CEO Pranav Tyagi [Photo: Tango]
Tango CEO on How His Firm’s WatchWire Acquisition Creates a Real Estate Management Powerhouse
by David Seeley | Aug 14, 2023
North Texas-based Tango—a Berkshire portfolio company—says the acquisition expands the global footprint of its own next-gen real estate management platform. And by leveraging WatchWire's proprietary data ingestion engine, the merged entity brings Tango squarely into the sustainability and energy management space. The result? "Bridging the gap" between landlords and tenants, says Tango founder and CEO Pranav Tyagi.
MORE►
by Lance Murray |
Jul 10, 2023
RobotLAB CEO and Founder Elad Inbar says the summit will shed light on the advantages that robotics and AI bring to various industries. And lunch will be served on robots.
MORE►
by Lance Murray |
Jun 1, 2023
Expanding a collaboration they announced in January, the two companies aim to drive "the future of cancer care" with the new platform, enabling novel insights for precision medicine, therapeutic development, and clinical trials management for academic and biopharma researchers.
MORE►
by Lance Murray |
May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE►
Illustration: LanternPharma
Lantern Pharma Adds VP of Clinical Development, Additional Team Members
by Lance Murray | Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members.
Lantern Pharma is a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development....
MORE►
by Lance Murray |
Jan 23, 2023
Caris Life Sciences, the Irving-based biotech company, announced Thursday that it closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion....
MORE►
by Quincy Preston |
Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
![From left: Abidali Neemuchwala and Dayakar Puskoor [Photo: Dallas Venture Capital]](https://s24806.pcdn.co/wp-content/uploads/2022/05/DVC-Abidali-Neemuchwala-DayakarPuskoor-360x203.jpg)
by Kevin Cummings |
May 25, 2022
Dallas Venture Capital is "poised to bootstrap two large start-up ecosystems in the U.S. and India," says co-founder Dayakar Puskoor.
The venture firm—which has an office in Irving and another in Hyperabad, India—plans a combined deployment of the funds over four to five years.
The venture firm—which has an office in Irving and another in Hyperabad, India—plans a combined deployment of the funds over four to five years.
MORE►
![Erica Kosemund, Chief Brand Officer, Choctaw Nation of Oklahoma; Gillian Breidenbach, Chief Partnership Officer, North Texas FWC Organizing Committee; Chief Gary Batton, Chief of Choctaw Nation of Oklahoma; Monica Paul, Executive Director of Dallas Sports Commission and President of North Texas FWC Organizing Committee; John Hobbs, Senior Executive Officer of Communications, Choctaw Nation of Oklahoma; and Heidi Grant, Senior Executive Officer of Commerce Administration, Choctaw Nation of Oklahoma, celebrate Choctaw Casinos & Resorts becoming an Official Dallas World Cup 2026 Host City Supporter. [Photo: North Texas FWC Organizing Committee/Choctaw Casinos & Resorts]](https://s24806.pcdn.co/wp-content/uploads/2025/12/FIFA-Choctaw-dec-2025.jpg)
